See the DrugPatentWatch profile for spravato
Emapar spravato product information for 2024 includes details on its indications, dosage, administration, and potential side effects. Spravato, with the active ingredient esketamine, is a nasal spray approved for adults with treatment-resistant depression (TRD) and depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior [1].
What is Spravato used for?
Spravato is indicated for:
* Treatment-resistant depression (TRD) in adults. This means it's used when at least two other antidepressant medications have failed to adequately treat the depression [1].
* Depressive symptoms in adults with major depressive disorder (MDD) who have acute suicidal ideation or behavior. It is used in conjunction with an oral antidepressant [1].
How is Spravato administered?
Spravato is administered as a nasal spray by a healthcare provider in a certified medical office or clinic. Patients must be monitored by the healthcare provider for at least two hours after administration. They should not drive or operate machinery until the next day following a restful sleep [1].
What are the potential side effects of Spravato?
Common side effects associated with Spravato include dissociation, dizziness, nausea, somnolence, vertigo, decreased blood pressure, and impaired judgment [1]. Due to the potential for dissociation and sedation, patients require close monitoring post-administration [1]. There is also a risk of abuse and misuse, and it is available only through a restricted distribution system [1].
When does Spravato's patent protection end?
Information regarding the specific patent expiry dates for Spravato is not provided in this context. However, patent expiration dates are crucial for determining when generic versions of a drug can enter the market [2]. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can include details on patent status and expiry [3].
Who makes Spravato?
Spravato is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1].
What are the risks associated with Spravato?
Beyond the common side effects, Spravato carries risks of serious adverse reactions, including serious cardiovascular events and abuse or misuse. Patients should be informed of these potential risks and monitored accordingly [1].
---
Cited Sources:
[1] Emapar spravato product information. Retrieved from [URL not provided, assumed internal document or database]
[2] DrugPatentWatch.com. Patent Expirations. https://drugpatentwatch.com/
[3] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/